Novel cosmetic or dermatological composition containing live probiotic bacterial strains

Abstract

The present invention relates to a cosmetic or dermatological composition comprising at least one live probiotic bacterial strain and at least one linear fat-dispersible and fat-soluble molecule selected from any one of dioctyl carbonate, coconut octoate, coconut caprate, undecane and / or tridecane, linoleic acid, behenyl alcohol or mixtures thereof, wherein the total content of the linear fat dispersible and fat soluble molecules is at least 40% by weight relative to the total weight of the composition. The invention also relates to the use of a linear fat dispersible and fat soluble molecule selected from any one of dicapryl carbonate, coconut octoate, coconut caprate, undecane and / or tridecane, linoleic acid, behenyl alcohol or mixtures thereof for maintaining the viability of a live probiotic bacterial strain in a composition intended for topical application.

Description

Technical Field

[0001] The invention belongs to the field of dermatological or cosmetic compositions containing probiotic bacterial strains and at least 40% by weight of at least one linear, fat-soluble and lipid-dispersible molecule and their use. Background Art

[0002] It is generally acknowledged that probiotics can be used in topical applications of the skin. Therefore, various clinical studies have reported the beneficial effects of probiotics on the skin in cosmetics and also in the field of dermatology. Probiotics do have advantages as cosmetic ingredients (M. Rahmati Roudsari et al., Health effects of probiotics on the skin, Crit. Rev. Food. Sci. Nutr., 2015, 55 (9), 1219-40]. The use of probiotics can also have great potential in the prevention and treatment of skin diseases, particularly eczema, atopic dermatitis, acne and allergic inflammation. Other applications are mentioned, such as the treatment of skin hypersensitivity, UV-induced skin lesions and wound protection.

[0003] However, due to the technical difficulties associated with the nature of probiotic products for topical application, there are few products of this type available on the market. The main difficulty is to maintain the viability of the probiotics in the composition, both during the manufacture of the composition and also for the duration of storage, while preventing their proliferation. This is because most conventional cosmetic and / or dermatological formulations cause a loss of viability of the probiotics during manufacture and / or during storage, in particular due to the presence of compounds that are harmful to bacteria or kill bacteria. On the contrary, in the absence of these compounds, in particular in aqueous formulations, the probiotics can proliferate, making them impossible to preserve.

[0004] Additionally, topical compositions must allow the probiotics to remain adequately retained on the skin over time, which is not possible with conventional formulations [Garima Sharma, Manuhaar Sharma, Rishav Sood, Jayanthi Neelamraju, Suvarna G. Lakshmi, Ratna Sudha Madempudi, Praveen Rishi, and Indu Pal Kaur (2021), Self-preserving gelatin emulgel containing whole cell probiotic for topical use: preclinical safety, efficacy, and germination studies, Expert Opinion on Drug Delivery, 18, 11, 1777-1789].

[0005] These difficulties therefore hinder the use of probiotics to be applied topically, especially in the cosmetic and dermatological fields.

[0006] Therefore, the present invention aims to solve this technical problem by providing a composition that allows the skin to be supplemented with probiotics in a safe, effective and practical way by topical application, while allowing the probiotics thus formulated to improve the health and / or aesthetics of the local skin.

[0007] Solutions already exist in these fields, but these solutions show shortcomings (such as too strict formulation or application restrictions) and are insufficient. Therefore, solutions for the application of microneedles, patches or encapsulations of probiotics have been described (WO 2020127637 A1; Hui-Jiuan Chen et al., Transdermal Delivery of Living and Biofunctional Probiotics through Dissolvable Microneedle Patches [transdermal delivery of living and biofunctional probiotics by dissolvable microneedle patches], ACS Applied Bio Materials [American Chemical Society Applied Biomaterials], 2018, 1 (2), 374-381)). Oily gels comprising oil and oily viscosity agents have also been described (WO2020 / 249734 A1). Summary of the invention

[0008] In this context and unexpectedly and surprisingly, the Applicant Company has found that compositions intended for topical applications, in particular cosmetic and / or dermatological applications —— It contains at least 40% by weight of linear fat-soluble and fat-dispersible molecules, at least one of which is selected from a specifically selected linear fat-soluble and fat-dispersible molecule, optionally in combination with one or more other linear fat-soluble and fat-dispersible molecules —— This makes it possible to solve the technical problem in a safe, simple, reliable, practical and efficient manner.

[0009] This is because the Applicant Company has found that the use of one or more specifically selected linear, fat-soluble and fat-dispersible molecules, optionally in combination with one or more other linear, fat-soluble and fat-dispersible molecules, in a total minimum content of at least 40% by weight of linear, fat-soluble and fat-dispersible molecules relative to the total weight of a composition intended for topical application, such as a cosmetic and / or dermatological composition, makes it possible to maintain the viability of the living probiotic bacteria and thus solve the technical problem.

[0010] The linear lipid-soluble and lipid-dispersible molecules specifically selected according to the present invention are selected from:

[0011] - dicaprylyl carbonate,

[0012] - coco-caprylate, optionally in combination with coco-caprate, preferably a mixture of coco-caprylate and coco-caprate,

[0013] - undecane and / or tridecane,

[0014] - linoleic acid and / or oleic acid, and / or linear esters thereof (e.g. isostearyl linoleate) and / or oleyl alcohol,

[0015] - behenyl alcohol and / or its acid and ester derivatives, in particular behenic acid, otherwise known as behenic acid, or behenic acid esters or behenic acid esters,

[0016] and / or any mixture thereof.

[0017] Due to their emollient properties, linear liposoluble and lipodispersible molecules are commonly used in cosmetic and dermatological compositions. However, it was not known that, unlike other liposoluble and lipodispersible molecules, in particular branched molecules, as described in the prior art, these molecules, and in particular those selected, when present in a minimum content of 40% by weight relative to the total weight of the cosmetic and / or dermatological composition, make it possible to maintain the viability of the living bacteria contained in the composition and thus solve the problems of the prior art. This is because the examples show that, in the absence of the selected linear liposoluble and lipodispersible molecules, branched fatty substances are not able to satisfactorily maintain the viability of the bacteria.

[0018] The present invention thus makes it possible, both for the manufacturer and also for the user, to develop topically administrable cosmetic and dermatological compositions which provide in a particularly advantageous manner stability, in particular long-term viability of the probiotics without allowing the latter to proliferate, for a satisfactory period of time compatible with the distribution and storage restrictions in the cosmetic and dermatological fields. Thus, in these compositions, the probiotic bacterial strains are stable, in other words, the strains remain alive and do not overgrow and therefore remain stable until their use.

[0019] As shown in the examples, such compositions according to the invention remain stable and in particular maintain the viability of the probiotic bacterial strains they contain and thus preserve the probiotic bacterial strains they contain, advantageously for:

[0020] - at ambient temperature, in other words at a temperature between 18° C. and 25° C., in particular at about 21° C., for at least 3 months, and

[0021] - Up to sixteen months, indeed even up to 18 months at 4°C.

[0022] The linear lipid-soluble and lipid-dispersible molecules used are of an oily nature or are waxes and thus allow the probiotic bacterial strains to be formulated in anhydrous or very low-water formulations, thereby making it possible to dispense with preservatives that would destroy the probiotic bacterial strains by reducing their viability.

[0023] Unlike the solutions described in the prior art, the compositions according to the invention are moreover easy to apply and can be easily formulated.

[0024] The subject of the present invention is a cosmetic and / or dermatological composition comprising:

[0025] - at least one live probiotic bacterial strain,

[0026] at least one linear lipid-dispersible and fat-soluble molecule chosen from: dicaprylyl carbonate; coco-caprylate, optionally in combination with coco-caprate, preferably a mixture of coco-caprylate and coco-caprate; undecane and / or tridecane; linoleic acid and / or oleic acid, and / or linear esters thereof and / or oleyl alcohol; behenyl alcohol and / or acid and ester derivatives thereof, in particular behenic acid, or behenic acid ester or behenic acid ester; and / or mixtures thereof,

[0027] - and optionally one or more other linear lipid-dispersible and lipid-soluble molecules,

[0028] The total content of the straight-chain lipid-dispersible and lipid-soluble molecules is at least 40% by weight relative to the total weight of the composition.

[0029] In particular, in the cosmetic and / or dermatological composition according to the invention, the other linear lipid-dispersible and lipid-soluble molecules are chosen from:

[0030] -Chemical formula C n H 2n+2 alkane molecules, wherein n represents a value ranging from 6 to 40,

[0031] -Chemical formula CH3-C x H 2x -COO-C y H 2y -CH3 ester molecule, wherein each of the x and y subscripts independently represents a value ranging from 5 to 19,

[0032] -Chemical formula CH3-C x H 2x -C(O)OH acid molecules, wherein x represents a value ranging from 5 to 24, preferably from 5 to 21, such as cerotic acid,

[0033] -Chemical formula CH3-C x H 2x -OH alcohol molecule, wherein x represents a value ranging from 5 to 21,

[0034] and any mixtures thereof.

[0035] In particular, in the cosmetic and / or dermatological composition according to the invention, the linear lipo-dispersible and liposoluble molecules chosen from the following are present in a content of at least 8% by weight, preferably at least 10% by weight, more preferably at least 15% by weight relative to the total weight of the composition: dicaprylyl carbonate; coco-caprylate, optionally in combination with coco-caprate, preferably a mixture of coco-caprylate and coco-caprate; undecane and / or tridecane; linoleic acid and / or oleic acid, and / or linear esters thereof and / or oleyl alcohol; behenyl alcohol and / or acid and ester derivatives thereof, in particular behenic acid, or behenic acid ester or behenic acid ester; and / or mixtures thereof.

[0036] In particular, in the cosmetic and / or dermatological composition according to the invention, the linear lipid-dispersible and lipid-soluble molecule is dicaprylyl carbonate.

[0037] In particular, in the cosmetic and / or dermatological composition according to the invention, the linear lipid-dispersible and lipid-soluble molecule chosen is coco-caprylate, optionally in combination with coco-caprate, preferably a mixture of coco-caprylate and coco-caprate.

[0038] In particular, in the cosmetic and / or dermatological composition according to the invention, the linear lipid-dispersible and lipid-soluble molecule chosen is dicaprylyl carbonate.

[0039] In particular, in the cosmetic and / or dermatological composition according to the invention, the linear lipid-dispersible and lipid-soluble molecule chosen is undecane and / or tridecane.

[0040] In particular, in the cosmetic and / or dermatological composition according to the invention, the linear lipid-dispersible and lipid-soluble molecule chosen is linoleic acid and / or oleic acid, and / or isostearyl linoleate and / or oleyl alcohol, preferably linoleic acid.

[0041] In particular, in the cosmetic and / or dermatological composition according to the invention, the linear lipid-dispersible and lipid-soluble molecule selected is behenyl alcohol and / or its acid and ester derivatives, in particular behenic acid, or behenic acid esters or behenic acid esters, preferably behenyl alcohol or behenyl alcohol.

[0042] In particular, in the cosmetic and / or dermatological composition according to the invention, the linear lipo-dispersible and liposoluble molecules chosen from the following are present in a content of at least 40% by weight, preferably at least 50% by weight, more preferably at least 60% by weight relative to the total weight of the composition: dicaprylyl carbonate; coco-caprylate, optionally in combination with coco-caprate, preferably a mixture of coco-caprylate and coco-caprate; undecane and / or tridecane; linoleic acid and / or oleic acid, and / or linear esters thereof and / or oleyl alcohol; behenyl alcohol and / or acid and ester derivatives thereof, in particular behenic acid, or behenic acid ester or behenic acid ester; and / or mixtures thereof.

[0043] In particular, the cosmetic and / or dermatological composition according to the invention comprises at least two, preferably three or four, linear lipodispersible and liposoluble molecules chosen from: dicaprylyl carbonate; coco-caprylate, optionally in combination with coco-caprate, preferably a mixture of coco-caprylate and coco-caprate; undecane and / or tridecane; linoleic acid and / or oleic acid, and / or linear esters thereof and / or oleyl alcohol; behenyl alcohol and / or its acid and ester derivatives, in particular behenic acid, or behenic acid ester or behenic acid ester.

[0044] In particular, the cosmetic and / or dermatological composition according to the invention additionally comprises a branched, fat-soluble and lipid-dispersible molecule selected from octyldodecanol, propylheptyl octanoate, a mixture of caprylic and capric triglycerides, hydrogenated castor oil, shea butter, coconut oil and / or cocoglycerides.

[0045] In particular, in the cosmetic and / or dermatological composition according to the invention, the live probiotic bacterial strain is chosen from Lactobacillus crispatus, Corynebacterium accolens, Sphingomonas glacialis, Streptococcus salivarus and mixtures thereof.

[0046] In particular, in the cosmetic and / or dermatological composition according to the invention, the live bacterial strain is formulated with a powder obtained by freeze drying on a maltodextrin carrier, preferably in a range of 10% to 80% by weight relative to the total weight of the powder, preferably in a range of 30% to 70% by weight, more preferably in a range of 40% to 60% by weight relative to the total weight of the powder.

[0047] In particular, in the cosmetic and / or dermatological composition according to the invention, the live bacterial strain is at 10 3 Up to 10 15 The content of CFU (colony forming units) / gram of composition.

[0048] In particular, in the cosmetic and / or dermatological composition according to the invention, the live bacterial strain is present in a content ranging from 0.01% to 3% by weight relative to the total weight of the composition.

[0049] In particular, in the cosmetic and / or dermatological composition according to the invention, the water activity (Aw) in the composition is less than 0.6.

[0050] In particular, the cosmetic and / or dermatological composition according to the invention is in the form of an oily suspension or solution, an oily cream or gel, an emulsion, a water-in-oil emulsion or an emulsion of the multi-type or silicone type, a mask, a serum, a lotion, a solid soap, a shampoo in solid form, a foam product in solid form, a dermatological bar, an ointment, a mousse, a patch, an anhydrous product - it is preferably a liquid, a paste or a solid, for example in the form of a cosmetic powder, a stick or a bar.

[0051] The invention further relates to the non-therapeutic use of a cosmetic composition according to the invention for preventing and / or reducing unaesthetic and / or uncomfortable manifestations of healthy skin, healthy superficial body growths and / or healthy mucous membranes, in particular sensitive or sensitized skin, superficial body growths and / or mucous membranes, fragile or weakened skin, superficial body growths and / or mucous membranes, dry skin, superficial body growths and / or mucous membranes, and / or skin, superficial body growths and / or mucous membranes with atopic tendency.

[0052] The invention additionally relates to the non-therapeutic use of the cosmetic composition according to the invention as a moisturizer and / or soothing agent for healthy skin, healthy body growths and / or healthy mucous membranes.

[0053] In particular, the non-therapeutic use according to the invention is carried out by topical application, preferably to areas of healthy skin, mucous membranes and / or body surface growths selected from the following: legs; feet; axillae; hands; thighs; buttocks; hemi-buttocks; waist; crotch; groin; stomach; neckline; neck; arms; trunk; back; face, in particular including the forehead, cheeks, nose, temples, T-zone (forehead, nose and chin), external auditory canal and / or chin; scalp; hair; nails; and / or labial mucosa, advantageously the axillae, neckline, hair, nails, labial mucosa and / or face, more advantageously the face.

[0054] The present invention additionally relates to the use of at least one linear lipid-dispersible and lipid-soluble molecule chosen from dicaprylyl carbonate; coco-caprylate, optionally in combination with coco-caprate, preferably a mixture of coco-caprylate and coco-caprate; undecane and / or tridecane; linoleic acid and / or oleic acid, and / or linear esters thereof and / or oleyl alcohol; behenyl alcohol and / or acid and ester derivatives thereof, in particular behenic acid, or behenic acid ester or behenic acid ester; and / or mixtures thereof, and optionally one or more other linear lipid-dispersible and lipid-soluble molecules for maintaining the viability of live probiotic bacterial strains, wherein the sum of the weight of the linear lipid-dispersible and lipid-soluble molecules is at least 40% by weight relative to the total weight of the cosmetic or dermatological composition.

[0055] The Applicant Company has also found that the composition according to the invention containing at least one live probiotic bacterial strain can therefore be used as a cosmetic composition, in particular for improving the appearance and / or comfort of healthy skin, including a healthy scalp and / or mucous membranes and / or healthy body growths, in particular hair and nails, and / or for the cosmetic care of healthy skin and / or mucous membranes and / or healthy body growths, including the most delicate skin, such as sensitive, sensitized, fragile, weakened or dry skin, and / or healthy skin with atopic tendencies. The linear, fat-soluble and lipid-dispersible molecules selected are emollients, which advantageously make it possible to additionally improve the hydration of the skin and / or mucous membranes and / or soften them.

[0056] Another subject of the present invention is a cosmetic care method, characterized in that it comprises the topical application of a cosmetic composition according to the invention to at least one area of ​​healthy skin and / or mucous membranes and / or healthy body surface growths for the cosmetic treatment of sensitive healthy skin and / or healthy mucous membranes, sensitized healthy skin and / or healthy mucous membranes, fragile and / or weakened healthy skin and / or healthy mucous membranes, healthy skin and / or healthy dry mucous membranes, healthy skin and / or healthy mucous membranes with atopic tendency, and / or as a soothing agent or moisturizer.

[0057] The Applicant Company has also found that the compositions according to the invention, in particular dermatological compositions, are particularly suitable for infections of the skin, mucous membranes and / or growths on the body surface caused by pathogenic microorganisms (in particular fungal diseases (Staphylococcus aureus), such as eczema, seborrheic or atopic dermatitis, acne), as well as inflammations and / or erythema of the skin or mucous membranes caused by pathogenic bacteria (such as Staphylococcus aureus), in particular in the treatment and / or prevention of diaper rash in babies, and / or in the prevention and / or medical treatment, in particular dermatological treatment, of conditions associated with reactive and / or atopic skin. Therefore, these compositions according to the invention can be used for the dermatological care of atopic and / or reactive skin and / or baby skin to prevent diaper rash in babies.

[0058] The present invention therefore provides a dermatological composition according to the invention for use as an anti-inflammatory or antibacterial composition and / or for use in the treatment and / or prevention of infections of the skin and / or mucous membranes, in particular those associated with pathogenic microorganisms such as yeasts or bacteria (e.g. fungal diseases or Staphylococcus aureus infections, such as eczema, dandruff, seborrheic or atopic dermatitis, acne), and of inflammations and / or erythema of the skin or mucous membranes caused by pathogenic bacteria such as Staphylococcus aureus, in particular diaper rash in babies, and / or in the prevention and / or medical treatment, in particular dermatological treatment, of conditions associated with reactive and / or atopic skin.

[0059] In particular, the present invention relates to a dermatological composition according to the invention for use as an anti-inflammatory or antibacterial agent and / or for use in the treatment and / or prevention of infections of the skin and / or mucous membranes and / or growths on the body surface caused by pathogenic microorganisms, such as pathogenic yeasts or bacteria, such as Staphylococcus aureus, such as fungal diseases, eczema, seborrheic or atopic dermatitis, acne, and inflammations of the skin or mucous membranes, fungal diseases and / or erythema, in particular diaper rash in babies, caused by pathogenic microorganisms, such as pathogenic yeasts or bacteria, such as Staphylococcus aureus, and / or in the prevention and / or medical treatment, in particular dermatological treatment, of conditions associated with reactive and / or atopic skin and / or mucous membranes.

[0060] Another subject of the present invention is a method for the treatment and / or prevention of infections of the skin and / or mucous membranes, in particular associated with pathogenic microorganisms (such as yeasts or bacteria) (for example fungal diseases or Staphylococcus aureus infections, such as eczema, dandruff, seborrheic or atopic dermatitis, acne), as well as inflammations and / or erythema of the skin or mucous membranes caused by pathogenic bacteria (such as Staphylococcus aureus), in particular diaper rash in infants, and / or a method for the prophylactic and / or medical treatment, in particular dermatological treatment, of conditions associated with reactive and / or atopic skin in a patient in need thereof, which comprises administering to said patient a pharmaceutically or dermatologically effective amount of a dermatological composition according to the invention.

[0061] Another subject of the present invention is the use of the dermatological composition according to the invention for the preparation of anti-inflammatory and / or antibacterial compositions and / or for the treatment and / or prevention of infections of the skin and / or mucous membranes and / or growths on the body surface caused by pathogenic microorganisms (e.g. pathogenic yeasts or bacteria, such as Staphylococcus aureus), such as fungal diseases, eczema, seborrheic or atopic dermatitis, acne, as well as inflammations of the skin or mucous membranes, fungal diseases and / or erythema, in particular diaper rash in babies, caused by pathogenic microorganisms (e.g. pathogenic yeasts or bacteria, such as Staphylococcus aureus) and / or medicaments for the prevention and / or medical treatment, in particular dermatological treatment of conditions associated with reactive and / or atopic skin and / or mucous membranes.

[0062] The composition according to the invention is advantageously intended for topical administration.

[0063] Within the meaning of the present invention, the terms "cosmetic use" and / or "cosmetic composition" are to be understood as meaning non-pharmaceutical uses and / or compositions, in other words non-pharmaceutical uses and / or compositions that are not intended for therapeutic use and that are applied to "healthy" parts of the body, in particular to "healthy" areas of the skin.

[0064] Within the meaning of the present invention, the term "healthy skin and / or mucous membranes" is understood to mean areas of human skin and / or mucous membranes to which an agent or composition according to the invention is applied and which are referred to by dermatologists as "non-pathological", in other words not exhibiting infections, scars, skin diseases or skin disorders such as candidiasis, impetigo, psoriasis, eczema, inflammation, ichthyosis, acne or dermatitis, or wounds or lesions.

[0065] Within the meaning of the present invention, the term "skin" is to be understood as meaning the skin of all or part of the body, in particular the human body, which is preferably selected from the legs; feet; armpits; hands; thighs; buttocks; half buttocks; waist; crotch; groin; stomach; decollete; neck; arms; torso; back; face, including forehead, cheeks, nose, temples, T-zone (forehead, nose and chin), external auditory canal and / or chin; and / or scalp, more preferably selected from the legs, feet, armpits, hands, thighs, stomach, decollete, neck, arms, torso, back, face and / or scalp, advantageously armpits, decollete, face, more advantageously face.

[0066] Within the meaning of the present invention, the term "mucosa" is to be understood as meaning the mucosa of the nose, eyes, vagina, urogenital and / or oral cavity, in particular the mucosa of the lips and / or gums, preferably the mucosa of the urogenital and / or oral cavity, preferably the mucosa of the lips.

[0067] According to the invention, the term "body growths" is understood to mean hair fibers (hair), eyelashes, eyebrows, body hair (especially beard and / or moustache), and / or nails, preferably nails and hair.

[0068] Within the meaning of the present invention, the term "lipid-soluble and lipid-dispersible molecules" is understood to mean molecules that are soluble and dispersible in a liquid oil phase, typically sunflower oil, at ambient temperature (i.e. between 18 and 25°C) or after heating at between 60 and 85°C and at atmospheric pressure.

[0069] Within the meaning of the present invention, the term "straight-chain molecule" is understood to mean an alkane, ester, acid, carbonate or alcohol molecule, the one or more carbon-based chains of which do not contain any branches. Thus, the molecule contains one or two straight carbon-based chains, in other words saturated or unsaturated carbon-based chains, in which each carbon atom is covalently bonded to at most two other carbon atoms. Thus, it does not contain any carbon groups branched onto one or more carbon chains.

[0070] In the sense of the present invention, the term "branched molecule" is understood to mean a molecule whose chain contains at least one branch. Thus, a molecule contains at least one branched carbon-based chain, in other words a saturated or unsaturated carbon-based chain, in which at least one of the carbon atoms is covalently bonded to at least three other carbon atoms. It may be saturated or unsaturated and contain at least one carbon group branched to the carbon-based chain.

[0071] Within the meaning of the present invention, the term "linear fat-soluble and lipid-dispersible molecules" is understood to mean the following molecules, alone or as a mixture, preferably at least two of the molecules selected from the following list:

[0072] -Chemical formula C n H 2n+2An alkane molecule of wherein n represents a value ranging from 6 to 40;

[0073] -Chemical formula CH3-C x H 2x -C(O)OC y H 2y -CH3 ester molecules, wherein each of the x and y subscripts independently represents a value ranging from 5 to 19;

[0074] - dicaprylyl carbonate;

[0075] -Chemical formula CH3-C x H 2x -C(O)OH acid molecules, wherein x represents a value ranging from 5 to 24, preferably ranging from 5 to 21; and

[0076] -Chemical formula CH3-C x H 2x -OH alcohol molecule, wherein x represents a value ranging from 5 to 21.

[0077] In particular, the linear fat-soluble and lipid-dispersible molecules may be chosen from: dicaprylyl carbonate; coco-caprylate, optionally in combination with coco-caprate, preferably a mixture of coco-caprylate and coco-caprate; undecane and / or tridecane; linoleic acid and / or oleic acid, and / or linear esters thereof (e.g. isostearyl linoleate) and / or oleyl alcohol; behenyl alcohol and / or acid and ester derivatives thereof, in particular behenic acid, otherwise expressed as behenic acid, or behenic acid esters or behenic acid esters; and / or mixtures thereof.

[0078] Within the meaning of the present invention, the term "selected linear fat-soluble and lipid-dispersible molecules" is understood to mean the following molecules, alone or as a mixture, preferably at least two of the molecules selected from the following list: dicaprylyl carbonate; coco-caprylate, optionally in combination with coco-caprate, preferably a mixture of coco-caprylate and coco-caprate; undecane and / or tridecane; linoleic acid and / or oleic acid, and / or linear esters thereof (e.g. isostearyl linoleate) and / or oleyl alcohol; behenyl alcohol and / or acid and ester derivatives thereof, in particular behenic acid, otherwise expressed as behenic acid, or behenic acid esters or behenic acid esters; and / or mixtures thereof.

[0079] Within the meaning of the present invention, the term "other linear lipid-dispersible and lipid-soluble molecules" is understood to mean linear lipid-dispersible and lipid-soluble molecules as defined above but different from the selected linear lipid-soluble and lipid-dispersible molecules also as defined above.

[0080] The term "derivatives" of acid molecules is understood according to the invention to mean alcohol and ester derivatives.

[0081] The term "derivatives" of alcohol molecules is understood according to the invention to mean acid and ester derivatives.

[0082] Within the meaning of the present invention, the term "to maintain viability" is understood to mean preventing an increase and / or decrease in the number of colony forming units (called CFU) of the viable bacterial strain in the composition over time. The viability of the viable bacterial strain according to the invention is said to be "maintained" if the number of CFU counted after a given time varies by at most 2 logs, preferably 1 log, relative to the number of CFU initially counted during the formulation of the composition according to the invention.

[0083] Maintenance of vitality is preferably evaluated after a given time ranging from one to twenty-four months, preferably one month, preferably 3 months, more preferably 6 months, more preferably 12 months and / or 16 months and / or 18 months from the formulation of the composition according to the invention.

[0084] Maintenance of viability is preferably assessed after storage at a temperature between 0°C and 30°C, preferably between 2°C and 25°C, preferably between 2°C and 6°C and / or between 10°C and 30°C and preferably at ambient temperature, in other words between 18°C ​​and 25°C, in particular about 21°C.

[0085] The number of CFU can be assessed according to conventional methods in the art, in particular by counting the bacterial strain placed in an appropriate culture medium, in particular by withdrawing a given amount of the composition, as described in Example 2.

[0086] Within the meaning of the present invention, the term "to maintain the stability of the composition comprising a live bacterial strain" is to be understood as meaning the prevention of an increase or decrease in parameters conventionally defined in the art, such as, for example, organoleptic parameters, such as color and / or odor and / or formulation pharmaceutical parameters, such as pH, maintenance of phases, absence of precipitation of compounds and / or growth of another microbial strain.

[0087] The live bacterial strains used in the present invention are referred to as probiotics. Within the meaning of the present invention, the term "probiotic or probiotic bacterial strain" is understood to mean one or more live and therefore viable (in other words capable of forming colonies in culture) bacterial strains. The bacterial strains referred to as probiotics according to the present invention are those that are of cosmetic and / or dermatological interest and that can be applied topically without risk to humans.

[0088] Within the meaning of the present invention, the term "live probiotic bacterial strain" is understood to mean the entire bacterial strain which is known to be viable, in other words a bacterial strain which is able to form colonies in culture.

[0089] Within the meaning of the present invention, the term "physiologically acceptable excipient" is understood to mean an excipient which is suitable for topical application, for cosmetic, pharmaceutical or dermatological use, which is non-toxic and non-irritating to the skin, which does not cause allergic reactions and which is not chemically unstable.

[0090] The term "topical application or topically" is understood to mean direct topical application and / or spraying of the composition onto the skin, in particular the scalp, and / or mucous membranes and / or the surface of body growths. Thus, the composition can be topically applied to all or part of the body and / or face, advantageously selected from the legs; feet; armpits; hands; thighs; buttocks; half buttocks; waist; crotch; groin; stomach; decollete; neck; arms; trunk; back; face, including forehead, cheeks, nose, temples, T-zone (forehead, nose and chin), labial mucosa, external auditory canal and / or chin; hair; and / or scalp, more preferably selected from the legs, feet, armpits, hands, thighs, stomach, decollete, neck, arms, trunk, back, face, hair, nails and / or labial mucosa and / or scalp, advantageously decollete, face, hair, nails and / or labial mucosa, more advantageously face; armpits, decollete, hair, nails, labial mucosa, scalp and / or face, very advantageously face.

[0091] Due to the complementary emollient properties of the selected liposoluble and lipodispersible molecules according to the invention, the cosmetic compositions according to the invention are particularly suitable for the cosmetic care and / or treatment of unaesthetic and / or uncomfortable manifestations of any type of skin, in particular what is known as normal and / or dry skin and / or mucous membranes, but also sensitive and / or sensitized and / or fragile and / or weakened skin and / or mucous membranes, and / or skin and / or mucous membranes with atopic tendency, and / or dry skin and / or mucous membranes.

[0092] In general, "sensitive skin and / or mucous membranes" can be defined as healthy skin and / or healthy mucous membranes, which by nature are only very slightly resistant to aggressive factors (especially environmental factors, such as pollutants, climatic factors (wind, cold, heat), exposure to UV radiation), emotional factors (especially stress) and / or chemical agents (heavy metals, detergents, compounds contained in cosmetic treatments, such as fragrances, preservatives, alcohols, pH, AHA or dermatological treatments, such as retinoic acid) and / or aggressive conditions (especially sweat and mechanical aggression, such as depilation, shaving, friction and even water, especially hard water). Unlike allergic skin, sensitive skin is not skin with pathological features. However, they can react to aggressive factors and / or conditions by unaesthetic and / or uncomfortable skin and / or mucous membrane manifestations, such as dryness of the skin and / or mucous membranes, loss of uniformity of skin color of the skin and / or mucous membranes, especially by a reddish appearance, a sensation of pulling, tingling, tingling, tightness and / or itching, a rough appearance of the skin and / or mucous membranes and / or a loss of softness to the touch. Thus, the “sensitive skin” characteristic can be assessed by the subjects themselves based on subjective skin sensation or by a dermatologist based on objective skin reactions.

[0093] Unaesthetic and / or uncomfortable manifestations may be generalized to the whole body, but most of the time they may have a well-defined location, such as, for example, the scalp, face, skin folds, hemi-buttocks of infants, etc. Thus, it may be a problem in areas of sensitive skin and / or mucous membranes.

[0094] Likewise, "sensitized skin and / or mucous membranes" are healthy skin and / or healthy mucous membranes that have become temporarily sensitized and are therefore non-pathological per se.

[0095] "Fragile or weakened skin and / or mucous membranes (in other words, skin or mucous membranes that have become temporarily fragile)" is healthy skin and / or healthy mucous membranes whose barrier function has been weakened. This state may be related to the state of the individual, and / or to age, elderly people and infants with fragile skin, for example. This state may also be caused by chemical or physical attack (abrasion, friction, cuts).

[0096] Likewise, the dermatological compositions according to the invention are particularly suitable for the dermatological care and / or treatment of pathological skin and / or mucous membranes, in particular atopic and / or reactive skin and / or mucous membranes.

[0097] "Skin and / or mucous membranes with atopic tendency" are extremely fragile and / or weakened healthy skin and / or healthy mucous membranes, the permeability of which is increased due to a weakened barrier function and which, under the influence of various intrinsic and extrinsic factors, is genetically predisposed to change towards the pathological state known as atopic dermatitis. Therefore, the characteristics of "skin with atopic tendency" can be assessed by the subject himself based on subjective skin sensation or by a dermatologist based on objective skin reactions.

[0098] The uncomfortable and / or unaesthetic manifestations of sensitized, fragile and / or weakened skin and / or mucous membranes are identical to the uncomfortable and / or unaesthetic manifestations of sensitive skin and / or mucous membranes, which are absent in the prevention and / or treatment of pathologies and / or skin conditions.

[0099] "Reactive skin and / or mucous membranes", otherwise expressed as intolerance or irritation or allergy, are skin and / or mucous membranes whose tolerance threshold has been lowered and which are overly reactive.

[0100] "Atopic skin and / or mucous membranes" are skin and / or mucous membranes affected by the pathology atopic dermatitis.

[0101] The characteristics of “reactive skin and / or mucous membranes” and “atopic skin and / or mucous membranes” can be assessed by a dermatologist based on objective skin reactions.

[0102] In the context of the present invention, a cosmetic and / or dermatological composition comprises:

[0103] - at least one live probiotic bacterial strain,

[0104] - at least one selected linear lipid-dispersible and lipid-soluble molecule,

[0105] - and optionally one or more other linear lipid-dispersible and lipid-soluble molecules,

[0106] The total content of the straight-chain lipid-dispersible and lipid-soluble molecules is at least 40% by weight relative to the total weight of the composition.

[0107] The linear liposoluble and lipodispersible molecules selected according to the invention are selected from:

[0108] - dicaprylyl carbonate,

[0109] - coco-caprylate, optionally in combination with coco-caprate, preferably a mixture of coco-caprylate and coco-caprate,

[0110] - undecane and / or tridecane,

[0111] - linoleic acid and / or oleic acid, and / or linear esters thereof (e.g. isostearyl linoleate) and / or oleyl alcohol,

[0112] - behenyl alcohol and / or its acid and ester derivatives, in particular behenic acid, otherwise known as behenic acid, or behenic acid esters or behenic acid esters,

[0113] and / or any mixture thereof.

[0114] This is because, as shown in Example 2, the Applicant Company has observed that these selected linear molecules make it possible to maintain the viability of the probiotic bacterial strains.

[0115] In particular, the linear liposoluble and lipodispersible molecules selected according to the invention are:

[0116] Straight chain acid:

[0117] -Dicaprylyl carbonate: Dicaprylyl carbonate otherwise represented by the formula C17H34O3 and CAS number 1680-31-5; this molecule is a diester of carbonic acid and octanol. It is usually marketed by BASF under the name CC sold or included in mixtures (such as products sold by BASF Gel CC).

[0118] - Coco-caprylate: INCI name is Coco-caprylate and otherwise indicated as Coco-alkyl caprylate (CAS 107525-85-9); this ester with a linear fatty chain is usually marketed by BASF under the name C5 sales.

[0119] - Coco-caprylate can be combined with Coco-caprate under the INCI name Coco-caprylate / caprate; this combination with the INCI name Coco-caprylate / caprate and CAS number 95912-86 is usually marketed by BASF under the name C5C sales.

[0120] These straight-chain acids are known and are used as emollients in cosmetic and dermatological compositions.

[0121] Straight chain alkanes:

[0122] - Undecane: It is an alkane with the formula C11H24 and CAS number 1120-21-4

[0123] -Tridecane: This alkane of formula C13H28 and CAS number 629-50-5 is usually sold by BASF under the name iSan Sales

[0124] - A mixture of undecane and tridecane is usually marketed by BASF under the name Ultimate Sales

[0125] Straight-chain fatty acids or their derivatives:

[0126] - Linoleic acid: It is a polyunsaturated fatty acid of the ω-6 group. It may be contained in particular in a mixture rich in linoleic acid (such as that sold by the Applicant Company under the name Lipofructyl TM Preferably, the linoleic acid is added in the form of a mixture enriched in linoleic acid (in other words representing at least 70% thereof) or in pure form.

[0127] - Oleic acid: It is a monounsaturated fatty acid of the ω-9 group. It may be contained in particular in a mixture enriched in linoleic acid (in other words representing at least 50%, preferably at least 70%), such as in the form of rapeseed oil enriched in ω-9, such as the rapeseed oil sold under the name Cegesoft PS6 by the company BASF.

[0128] Linear esters of linoleic acid or oleic acid are linear molecules comprising a radical having a chain of up to 20 carbons esterified on the acid function, such as, for example, isostearyl linoleate or decyl oleate.

[0129] -Oleyl alcohol

[0130] Straight chain fatty alcohol:

[0131] - Behenyl alcohol: It is otherwise known as behenyl alcohol and has the formula C 22 H 46 O; it is usually referred to by BASF under the name Its acid and ester derivatives are in particular chosen from behenic acid, otherwise expressed as behenic acid, its behenic acid esters or behenic acid esters and / or mixtures thereof.

[0132] Advantageously, the selected linear, liposoluble and lipodispersible molecule is contained in the cosmetic or dermatological composition in a minimum content of 8% by weight, more preferably at least 10% by weight, preferably at least 15% by weight, preferably 40% by weight, more preferably at least 50% by weight, advantageously at least 60% by weight, more preferably 70% by weight relative to the total weight of the composition.

[0133] The cosmetic or dermatological composition according to the invention advantageously comprises a mixture of at least two, preferably three or four of the selected linear lipophilic and lipophilic molecules, with the proviso that the total content of linear lipophilic and lipophilic molecules is at least 40% by weight, preferably at least 50% by weight, more preferably at least 60% by weight relative to the total weight of the cosmetic or dermatological composition.

[0134] According to one embodiment, the selected linear lipid-soluble and lipid-dispersible molecules are used as purified molecules or as molecules contained in a mixture containing them (such as an extract). In particular, they are used as purified molecules.

[0135] The selected linear lipophilic and lipophilic molecules according to the invention can be combined with other linear lipophilic and lipophilic molecules which have not been selected, provided that the total content of linear lipophilic and lipophilic molecules is at least 40% by weight, preferably at least 50% by weight, more preferably at least 60% by weight relative to the total weight of the cosmetic or dermatological composition.

[0136] These other linear fat-soluble and lipid-dispersible molecules that may be included in the composition in combination with those selected are preferably selected from:

[0137] -Chemical formula C n H 2n+2 An alkane molecule of , wherein n represents a value ranging from 6 to 40, preferably one of the paraffins wherein n is between 8 and 40, advantageously between 20 and 40 or between 8 and 19, such as, for example, dodecane, tetradecane and / or pentadecane;

[0138] -Chemical formula CH3-C x H 2x -COO-C y H 2y -CH3 ester molecules, wherein each of the x and y subscripts independently represents a value ranging from 3 to 19, such as myristyl myristate C28H56O2, cetearyl palmitate, cetyl palmitate, butyl palmitate or myristyl palmitate;

[0139] -Chemical formula CH3-C x H 2x -C(O)OH acid molecules, wherein x represents a value ranging from 5 to 24, preferably ranging from 5 to 21, such as cerotic acid;

[0140] -Chemical formula CH3-C x H 2x -OH alcohol molecule, wherein x represents a value ranging from 5 to 21;

[0141] and any mixtures thereof.

[0142] According to a preferred embodiment, the present invention relates to a composition intended for topical application, in particular a cosmetic or dermatological composition, comprising at least one live probiotic bacterial strain and at least 40% by weight of one or more selected linear fat-soluble and fat-dispersible molecules, preferably at least two selected linear fat-soluble and fat-dispersible molecules, relative to the weight of the total composition.

[0143] Advantageously, the composition according to the invention does not contain alkanes or glycerol.

[0144] The cosmetic or dermatological composition according to the invention advantageously comprises a mixture of at least two, preferably three or four, of the selected linear liposoluble and lipodispersible molecules, the sum of which is at least 40% by weight, preferably 50% by weight relative to the total weight of the cosmetic or dermatological composition.

[0145] According to a particular embodiment of the invention, the linear lipophilic and lipophilic molecules included in the cosmetic or dermatological composition are selected exclusively from the selected linear lipophilic and lipophilic molecules. In other words, the cosmetic or dermatological composition according to the invention does not contain linear lipophilic and lipophilic molecules other than those selected.

[0146] According to a particular embodiment of the invention, the cosmetic or dermatological composition consists of one or more selected linear lipid-soluble and lipid-dispersible molecules and a live probiotic bacterial strain.

[0147] The composition according to the invention contains at least one live probiotic bacterial strain. According to the invention, the term "live probiotic bacterial strain" is understood to mean a bacterial strain of cosmetic and / or dermatological interest, in other words non-pathogenic and whose local contribution can improve the aesthetics and / or comfort of healthy skin or treat a pathology. It can be considered wild-type or genetically modified bacteria.

[0148] Preferably, the following bacteria are considered:

[0149] a group of lactic acid bacteria, in particular Lactobacillus rhamnosus, Lactobacillus brevis, Lactobacillus crispatus, Lactobacillus delbrueckii, Lactobacillus fermentum, Lactobacillus helveticus, Lactobacillus plantarum, Lactobacillus iners, Lactobacillus gasseri, Lactobacillus jensenii, Lactobacillus reuteri, Lactobacillus brevis and / or Lactobacillus acidophilus, preferably Lactobacillus crispatus;

[0150] - cocci, in particular Alloicoccus otitis, Lactococcus lactis, Streptococcus thermophilus, Streptococcus salivarius, Staphylococcus epidermidis, Staphylococcus hominis, Staphylococcus warfarinii, Staphylococcus caprae and / or Staphylococcus saprophyticus;

[0151] - Micrococci, especially Micrococcus luteus;

[0152] - Bifidobacterium, in particular Bifidobacterium longum and / or Bifidobacterium infantis;

[0153] - the Corynebacterium group, in particular Corynebacterium congestum, Corynebacterium tuberculolyticum and / or Corynebacterium amycolyticum;

[0154] - Sphingomonas group, in particular Sphingomonas glacialis;

[0155] - Bacillus sp., in particular Bacillus cereus (Bacillus subtilis) and / or Bacillus licheniformis; and

[0156] - Propionibacterium bacteria, especially Propionibacterium acnes.

[0157] More preferably, the following bacteria are considered:

[0158] a group of lactic acid bacteria, in particular Lactobacillus rhamnosus, Lactobacillus brevis, Lactobacillus crispatus, Lactobacillus delbrueckii, Lactobacillus fermentum, Lactobacillus helveticus, Lactobacillus plantarum, Lactobacillus iners, Lactobacillus gasseri, Lactobacillus jensenii, Lactobacillus reuteri, Lactobacillus brevis and / or Lactobacillus acidophilus, preferably Lactobacillus crispatus;

[0159] - cocci, in particular Differococcus otitidis, Lactococcus lactis, Streptococcus thermophilus, Streptococcus salivarius, Staphylococcus epidermidis and / or Staphylococcus hominis;

[0160] - Bifidobacterium, in particular Bifidobacterium longum and / or Bifidobacterium infantis;

[0161] - Corynebacterium group, in particular Corynebacterium congestum;

[0162] - Sphingomonas group, in particular Sphingomonas glacialis;

[0163] - Bacillus group, in particular Bacillus cereus (Bacillus subtilis) and / or Bacillus licheniformis;

[0164] - Propionibacterium bacteria, especially Propionibacterium acnes.

[0165] Preferably, the live probiotic bacterial strain is selected from the group consisting of Lactobacillus crispatus, Corynebacterium crowder, Sphingomonas glacialis, Streptococcus salivarius and mixtures thereof.

[0166] Particularly advantageously, the live probiotic bacterial strain is one of the following strains deposited under the Budapest Treaty at the Pasteur Institute (25 rue du Docteur Roux, F-75724 Paris cedex 15):

[0167] - the Lactobacillus crispatus strain deposited under the number CNCM 1-5579,

[0168] - The Sphingomonas glacialis strain deposited under the number CNCM 1-5829.

[0169] The live probiotic bacterial strains may be formulated in a powdered state, in other words in dry form or in the form of a suspension.

[0170] Typically, the live probiotic bacterial strain may be isolated before it is placed in the composition, in other words not mixed with one or more compounds of the culture medium from which it originated. Alternatively, the live probiotic bacterial strain may be combined with the culture medium from which it originated, in particular with compounds of its culture medium.

[0171] According to a preferred embodiment, the live probiotic bacterial strain may be combined with a bacterial strain in an inactivated form, in particular in a dead form and / or in the form of a lysate thereof, and / or in the form of one or more of its fractions and / or in the form of one or more of its metabolites, in particular its secretome. Thus, it may consider the same bacterial strain in an inactivated form or another bacterial strain in an inactivated form. Preferably, it will consider the same bacterial strain as the live probiotic bacterial strain.

[0172] According to one embodiment, the composition according to the invention may contain several live probiotic bacterial strains or one live probiotic bacterial strain in combination with another bacterial strain in an inactivated form, in particular in a dead form and / or in the form of a lysate thereof, and / or in the form of one or more of its fractions and / or in the form of one or more of its metabolites, in particular of its secretome.

[0173] Particularly advantageously, the live probiotic bacterial strain is contained in the cosmetic or dermatological composition in a concentration ranging from 0.001% to 3% by weight (w / w), more preferably from 0.01% to 0.3% by weight (w / w) or about 0.025% by weight (w / w), relative to the total weight of the composition.

[0174] Advantageously, the live probiotic bacterial strain is present in an amount of 10 3 Colony forming units (CFU) to 10 15 CFU / g, preferably in the range of 10 4 Up to 10 10 CFU / g, more preferably in the range of 10 5 Up to 10 9 CFU / g, more preferably in the range of 10 5 Up to 10 8 CFU / g, more preferably about 10 5 The concentration of CFU / g is contained in the cosmetic or dermatological composition.

[0175] Advantageously, the live probiotic bacterial strain is present in an amount of 10 3 Up to 10 8 CFU / g, more preferably in the range of 10 4 Up to 10 8 CFU / g, more preferably in the range of 10 5 Up to 10 8CFU / g, more preferably about 10 5 The concentration of CFU / g is contained in the cosmetic composition.

[0176] Advantageously, the live probiotic bacterial strain is present in an amount of 10 9 Colony forming units (CFU) to 10 15 CFU / g, preferably in the range of 10 9 Up to 10 13 A concentration of CFU / g is contained in the dermatological composition.

[0177] The production of live probiotic bacterial strains can be carried out according to any method generally known to the person skilled in the art. Advantageously, it will be carried out according to a protocol as described, for example, in Example 1.

[0178] According to an advantageous embodiment, the cosmetic or dermatological composition according to the invention has a water activity of less than 0.6, more preferably less than 0.5, more preferably less than 0.4.

[0179] Water activity (AW) indicates the availability of the so-called "free" water of the substrate. Therefore, it is not the exact water content of the culture medium but only the water that can participate in chemical, biochemical or microbiological reactions. It is defined relative to a pure water reference state, therefore without any solutes. The value of AW varies between 0 and 1. When the product is dry and all water is bound to the substrate (no reactive properties), it is equal to 0. In the case of pure water, it is equal to 1.

[0180] The water activity is measured in a manner generally accepted by the person skilled in the art using a device for measuring water activity such as, for example, the Aqualab device sold by Metergroup.

[0181] According to a more preferred embodiment, the composition according to the invention contains at most 5% by weight, preferably less than 3% by weight of added water relative to the total weight of the composition, and more preferably contains no added water.According to a specific embodiment, the composition according to the invention is a non-aqueous composition.

[0182] According to a specific embodiment of the present invention, the live probiotic bacterial strain is included in the oil phase (or non-aqueous phase). Alternatively, the live probiotic bacterial strain according to the present invention can be dispersed and / or diluted in a solvent for use. Preferably, the solvent contains less than 20% by volume (v / v) of water, more preferably less than 5% by volume (v / v) of water; more preferably, the solvent does not contain water.

[0183] According to a preferred embodiment, the solvent contains less than 20% by weight (w / w) of water, more preferably less than 5% by weight (w / w) of water; more preferably, the solvent does not contain water. Very preferably, the solvent is one of the selected lipid-soluble and lipid-dispersible molecules according to the present invention.

[0184] The live probiotic bacterial strain according to the invention is preferably added to the composition according to the invention in dry form, in other words in powder form, advantageously in maltodextrin, preferably at a strain content of 10 to 80% by weight (w / w), preferably 30 to 70% by weight (w / w) of strain, more advantageously 40 to 60% by weight (w / w) of strain relative to the total weight of the powder.

[0185] According to a specific embodiment, the cosmetic or dermatological composition according to the invention may comprise, in its implementation:

[0186] - at least one live probiotic bacterial strain chosen from Lactobacillus crispatus, Corynebacterium crowder, Sphingomonas glaciaria, Streptococcus salivarius and mixtures thereof, preferably the strain of Lactobacillus crispatus deposited under number CNCM 1-5579 and Sphingomonas glaciaria, preferably the strain deposited under number CNCM 1-5829;

[0187] - The live probiotic bacterial strains are preferably:

[0188] ° is in the range of 10 4 Up to 10 10 CFU / g composition, more preferably in the range of 10 5 Up to 10 9 CFU / g composition, more preferably in the range of 10 5 Up to 10 8 CFU / g composition content,

[0189] ° added to the composition in the form of a freeze-dried powder on a maltodextrin carrier at a strain content ranging from 40% to 60% by weight (w / w) of the strain relative to the total weight of the maltodextrin powder;

[0190] at least one linear fat-soluble and lipid-dispersible molecule selected from: dicaprylyl carbonate; coco-caprylate, optionally in combination with coco-caprate, preferably a mixture of coco-caprylate and coco-caprate; undecane and / or tridecane; linoleic acid and / or oleic acid, and / or linear esters thereof (e.g. isostearyl linoleate) and / or oleyl alcohol; behenyl alcohol and / or acid and ester derivatives thereof, in particular behenic acid, otherwise expressed as behenic acid, or behenic acid esters or behenic acid esters; and any of mixtures thereof;

[0191] - at least one other linear lipid-soluble and lipid-dispersible molecule; and

[0192] - a total content of linear liposoluble and lipodispersible molecules of at least 40% by weight, preferably 50% by weight, relative to the total weight of the composition.

[0193] The cosmetic or dermatological composition according to the invention comprises, in its preferred embodiment:

[0194] - at least one live probiotic bacterial strain chosen from Lactobacillus crispatus, Corynebacterium crowder, Sphingomonas glaciaria, Streptococcus salivarius and mixtures thereof, preferably the strain of Lactobacillus crispatus deposited under number CNCM 1-5579 and Sphingomonas glaciaria, preferably the strain deposited under number CNCM 1-5829;

[0195] - The live probiotic bacterial strains are preferably:

[0196] ° is in the range of 10 4 Up to 10 10 CFU / g composition, more preferably in the range of 10 5 Up to 10 9 CFU / g composition, more preferably in the range of 10 5 Up to 10 8 CFU / g composition content,

[0197] ° added to the composition in the form of a freeze-dried powder on a maltodextrin carrier at a strain content ranging from 40% to 60% by weight (w / w) of the strain relative to the total weight of the maltodextrin powder;

[0198] at least one, preferably at least two, linear, fat-soluble and lipid-dispersible molecules selected from: dicaprylyl carbonate; coco-caprylate, optionally in combination with coco-caprate, preferably a mixture of coco-caprylate and coco-caprate; undecane and / or tridecane; linoleic acid and / or oleic acid, and / or linear esters thereof (e.g. isostearyl linoleate) and / or oleyl alcohol; behenyl alcohol and / or acid and ester derivatives thereof, in particular behenic acid, otherwise expressed as behenic acid, or behenic acid esters or behenic acid esters; and any of mixtures thereof;

[0199] - a total content of at least 40% by weight, preferably 50% by weight, of the selected linear liposoluble and lipodispersible molecules, relative to the total weight of the composition.

[0200] The cosmetic and dermatological compositions are produced according to customary formulation methods.

[0201] Preferably, the live probiotic bacterial strain is preferably directly dispersed in any of the linear and / or branched fat-soluble and fat-dispersible molecules, preferably linear fat-soluble and fat-dispersible molecules, more preferably selected linear fat-soluble and fat-dispersible molecules, in other words selected from: dicaprylyl carbonate; coco-caprylate, optionally in combination with coco-caprate, preferably a mixture of coco-caprylate and coco-caprate; undecane and / or tridecane; linoleic acid and / or oleic acid, and / or linear esters thereof (e.g. isostearyl linoleate) and / or oleyl alcohol; behenyl alcohol and / or acid and ester derivatives thereof, in particular behenic acid, otherwise expressed as behenic acid, or behenic acid esters or behenic acid esters; and mixtures thereof.

[0202] Preferably, the composition according to the invention is produced at a maximum temperature of 70° C. in the case of “hot” production or at ambient temperature (in other words between 18° C. and 25° C., in particular about 21° C.) in the case of “cold” production.

[0203] Advantageously, the manufacturing temperature does not exceed 70° C. for a maximum duration of 3 hours. It will be adjusted according to the resistance of the living bacterial strain under consideration.

[0204] In a preferred embodiment, the composition according to the invention will be produced in the case of "cold" manufacture at ambient temperature (in other words between 18°C ​​and 25°C, in particular 21°C).

[0205] The cosmetic and dermatological compositions according to the invention are compositions for topical application.

[0206] In an advantageous embodiment, the composition according to the invention additionally comprises a physiologically acceptable excipient, in particular a cosmetically, pharmaceutically or dermatologically acceptable excipient.

[0207] In the context of the present invention, live probiotic bacterial strains are used as active agents in compositions, in particular as cosmetic or dermatological active ingredients, for preventing and / or reducing unaesthetic and / or uncomfortable manifestations of healthy skin and / or healthy mucous membranes known as normal, sensitive and / or sensitized and / or fragile and / or weakened and / or dry and / or with atopic tendency.

[0208] The cosmetic or dermatological composition according to the invention can also be used in the form of a cosmetic or dermatological medicament or a premix intended to be incorporated into another cosmetic or dermatological composition and additionally comprising suitable cosmetic or pharmaceutical excipients, in particular immediately prior to its application.

[0209] In this case, according to a particularly advantageous embodiment for this mode of administration, the live probiotic bacterial strain is then contained in the composition according to the invention in a more concentrated dose, in particular in a concentration ranging from 0.001% to 3% by weight, more preferably from 0.01% to 0.3% by weight, preferably from 0.1% to 0.25% by weight, more preferably in a concentration of about 0.20% by weight relative to the total weight of the composition.

[0210] Preferably, the composition according to the invention is a ready-to-use cosmetic or dermatological composition, in other words a composition that can be used directly by topical application.

[0211] The composition according to the invention does not contain biocidal amounts of agents and / or preservatives which might adversely affect the viability of the live probiotic strains.

[0212] The composition according to the invention may contain any suitable solvent, excipient or vehicle, as well as other active ingredients, provided that it does not adversely affect the stability of the composition, in particular the viability of the live probiotic bacterial strains.

[0213] Advantageously, the composition according to the invention may also contain non-linear fat-soluble and fat-dispersible molecules, in particular branched fatty substances, provided that the linear fat-soluble and fat-dispersible molecules, in particular those selected, are present in the cosmetic composition in a minimum content of 40% by weight, preferably at least 50% by weight, more advantageously at least 60% by weight, more preferably at least 70% by weight relative to the total weight of the composition.

[0214] The term "branched fatty substances" is generally understood to mean liquid, pasty or solid oily compounds with branched chains, in particular waxes, in particular vegetable oils, and also saturated fatty acids with one or more hydrocarbon branches on the carbon-based chain, generally denoted BCFA (branched-chain fatty acids). These branched fatty substances are often used in many cosmetic and dermatological compositions as texturizing agents, emollients, structurants or rheology modifiers.

[0215] The branched fatty substances are advantageously those chosen from oils of the type of fatty substances having branched chains, such as:

[0216] -Octyldodecanol, otherwise expressed as G;

[0217] - Propylheptyl octanoate, especially marketed by BASF under the name Sensoft Sales;

[0218] - a mixture of caprylic and capric triglycerides known by the CAS number 73398-61-5, such as sold by BASF under the name 318 mixture sold;

[0219] - Hydrogenated castor oil;

[0220] - Shea butter or other fatty acids such as those marketed by BASF under the name SB 45 is sold as a mixture containing oleic, stearic, linolenic, palmitic, linoleic, and arachidonic acids;

[0221] - Coconut oil and / or coconut glycerides, in particular those marketed under the name Those sold by 331;

[0222] - Squalane or a squalane derivative, such as hemi-squalane.

[0223] Preferably, the composition according to the invention contains a maximum amount of 40% by weight, preferably 30% by weight, more preferably less than 20% by weight of branched fatty substances, in particular those listed above, relative to the total weight of the composition. This is because, according to this preferred embodiment, the composition exhibits improved activity at ambient temperature, as shown in Example 6.

[0224] According to a particular embodiment of the invention, the cosmetic or dermatological composition is free of non-linear lipophilic and lipophilic molecules and therefore free of branched fatty substances.

[0225] Other fat-soluble ingredients may be included in the composition according to the invention, such as, for example:

[0226] - vitamins or antioxidants, in particular vitamin E, otherwise expressed as tocopherol, to prevent oxidation of fatty substances;

[0227] - Feel agents, such as microcrystalline cellulose;

[0228] - texturizing agents, such as fat phase thickeners and / or gelling agents, such as, for example, stearalkonium hectorite and propylene carbonate, in particular from BASF in combination with dicaprylyl carbonate Gel CC is sold as a mixture;

[0229] - Other emollients.

[0230] Thus, the excipient may be selected from surfactants and / or emulsifiers, buffers, chelating agents, denaturants, opacifiers, pH adjusters, reducing agents, stabilizers, thickeners, gelling agents, film-forming polymers, fillers, matifying agents, glossing agents, pigments, dyes, fragrances and mixtures thereof. CTFA (Cosmetic Ingredient Handbook, 2016 edition) describes various cosmetic excipients suitable for use in the present invention.

[0231] Advantageously, the excipient is selected from the group comprising polyglycerols, esters, cellulose polymers and derivatives, lanolin derivatives, phospholipids, lactoferrin, lactoperoxidase, sucrose-based stabilizers, vitamin E and its derivatives, xanthan gum, natural and synthetic waxes, vegetable oils, triglycerides, unsaponifiable substances, phytosterols, silicones, protein hydrolysates, betaines, amine oxides, plant extracts, sucrose esters, titanium dioxide, glycine, and more preferably from the group consisting of steareth-2, steareth-21, glycol-15 stearyl ether, cetearyl alcohol, butylene glycol, caprylyl glycol, natural tocopherols. , glycerin, sodium dihydroxycetyl phosphate, isopropyl hydroxycetyl ether, glycol stearate, triisononanoin, octyl cocoate, polyacrylamide, isoparaffin, laureth-7, carbomer, propylene glycol, hexylene glycol, glycerin, bisabolol, dimethicone, sodium hydroxide, PEG-30 dipolyhydroxystearate, capric / caprylic triglyceride, cetearyl caprylate, dibutyl adipate, grape seed oil, jojoba oil, magnesium sulfate, EDTA, cyclomethicone, xanthan gum, citric acid, sodium lauryl sulfate, mineral oil and wax, isostearyl isostearate, propylene glycol dipelargonate, propylene glycol isostearate, PEG 8, beeswax, hydrogenated palm kernel glycerides, lanolin oil, sesame oil, cetyl lactate, lanolin alcohol, castor oil, titanium dioxide, lactose, sucrose and mixtures thereof.

[0232] According to a particularly advantageous embodiment, the composition according to the invention also comprises a biodegradable polymer chosen from:

[0233] - a topically acceptable alginic acid, its salts and esterified derivatives thereof, advantageously chosen from ammonium alginate, sodium alginate, calcium alginate, magnesium alginate, sodium alginate sulfate and potassium alginate, glycerol alginate or propylene glycol alginate, or a mixture thereof, advantageously sodium alginate and / or propylene glycol alginate;

[0234] - a topically acceptable hyaluronic acid, its salts and esterified derivatives thereof, advantageously chosen from hydrolyzed calcium hyaluronate, hydrolyzed sodium hyaluronate, potassium hyaluronate, sodium hyaluronate or sodium hyaluronic acid sulfate, preferably sodium hyaluronate;

[0235] - scleroglucan;

[0236] and / or any mixture thereof.

[0237] According to a preferred embodiment of the present invention, it has been found that such polymers further improve the viability of the live probiotic bacterial strains in the composition according to the invention, in particular when they are present in a content of between 0.1% and 10% by weight, more preferably between 1% and 5% by weight relative to the total weight of the cosmetic or dermatological composition.

[0238] The cosmetic or dermatological composition according to the invention may be chosen from oily suspensions or solutions, oily creams or gels, emulsions, water-in-oil emulsions or emulsions of the multi-type or silicone type, masks, serums, lotions, solid soaps, shampoos in solid form, foam products in solid form, emollient soap bars, ointments, mousses, patches, anhydrous products - preferably they are liquids, pastes or solids, for example in the form of cosmetic powders, sticks or bars.

[0239] Advantageously, the cosmetic or dermatological composition according to the invention is not in the form of a water-in-oil emulsion.

[0240] The cosmetic or dermatological composition may additionally comprise a cosmetically or dermatologically acceptable excipient selected from surfactants, buffers, swelling agents, chelating agents, denaturants, sunscreens, pH adjusters, reducing agents, stabilizers, emulsifiers, thickeners, gelling agents, film-forming polymers, solvents, fillers, odor absorbers, oil absorbers, conditioners, texture agents, gloss agents, pigments, dyes, fragrances, chemical or inorganic sunscreens, trace elements and essential oils. The present invention also encompasses these combinations.

[0241] The cosmetic or dermatological compositions may contain further fat-soluble and fat-dispersible active ingredients.

[0242] The cosmetic or dermatological composition may additionally comprise other ingredients active for the treatment of normal skin and / or mucous membranes, sensitive, sensitized, reactive, fragile and / or weakened skin and / or mucous membranes, and / or having an effect on the increase and / or protection and / or maintenance of the beneficial commensal flora on the skin and / or mucous membranes, inducing a complementary or synergistic effect with the probiotic bacterial strains according to the invention, for example selected from:

[0243] - a combination of sodium hyaluronate, pullulan and sodium alginate, in particular in a formulation containing serine, trehalose, urea and glycerol under the name PatcH2O TM for sale, or a combination of hyaluronic acid, pullulan and propylene glycol alginate with lactic acid, succinic acid and / or sucrose;

[0244] - Other cosmetic ingredients intended for the care of sensitive skin, such as plant extracts of Cestrum latifolium, as described in application WO 2009 / 112590, for example by the applicant under the name Symbiocell TM marketed by the applicant under the name Irwinol TM Butter extracted from the fruit of the tree Irvingia gabonensis; sold under the name Eperuline TMAn extract of the root of Eperuafalcata sold by the applicant under the name Skinasensyl TM The peptide N-acetyl-L-tyrosyl-L-prolyl-L-phenylalanyl-L-phenylalaninamide (INCI: Acetyl Tetrapeptide-15) is sold.

[0245] The cosmetic composition will also be able to contain one or more ingredients active on the microflora of the skin and / or mucous membranes and / or on the barrier function of the skin, in particular moisturizing and / or soothing active ingredients, among which are those marketed by Solabia under the name BioEcolia TM Oligosaccharides obtained by enzymatic synthesis are marketed or by the same company under the name Ecoskin TM Alpha-glucose oligosaccharide complex for sale, extract of Alisma plantago-aquatica, extract of Argania spinosa (Lipofructyl TM Argan, a mixture of ceramides (Sphingoceryl TM VEG, purified extract of Betapur TM ), products based on inulin or fructooligosaccharides, extracts of bifidobacteria or also extracts of Orthosiphon stamineus to combat oily skin (MAT-XS TM Bright) by the applicant company under the name Melhydran TM A natural extract of honey marketed for its moisturizing properties by the applicant company under the name Oligolin TM Flax extract, an extract of the seeds of Cassia angustifolia, is marketed by the applicant company under the name marketed, modified by biotechnology and marketed by the applicant company under the name Relipidium TM The yeast extract, Hydagen GG, is marketed by the applicant company under the name Inhipase TM Pueraria lobata root extract is marketed by Mibelle under the name CM-Glucan Forte TM β-glucan derivatives produced by baker's yeast are marketed and / or marketed by Sederma under the name Pacifeel TM Extracts of Mirabilis jalapa, inulin, marketed in particular by the applicant company under the name Scalposine TMN-methylglycine is marketed as a skin prebiotic by the applicant company under the name Phytosoothe TM The medicament for repairing barrier function extracted from phytosterols of rapeseed (Brassica campestris) seed oil, containing β-glucan and marketed by the applicant company under the name Hydrasensyl glucan TM A moisturizer and soothing agent marketed under the name Ultra Filling Spheres TM A moisturizer containing hyaluronic acid and konjac polysaccharide is marketed by the applicant company under the name Inolixir TM Antioxidant, anti-inflammatory, anti-redness agent containing an extract of Chaga (Inonotus obliquus) marketed by soothing, a medicament for protecting against the effects of pollutants, in particular by the applicant company under the name Purisoft TM The extract of Moringa oleifera seeds is marketed by the applicant company under the name The extract of Cassia angustifolia is marketed by the applicant company under the name Phytofim TM Soybean extract fermented by lactic acid bacteria sold by biotic.

[0246] According to a particularly advantageous embodiment, the active ingredient contained in the composition is of oily and / or lipid dispersible nature, such as the one commercialized by the applicant company under the name The oily extract of Cyperus esculentus sold by the applicant company under the name of Argassential TM An extract of the fruit of the Argania spinosa tree sold as HYALURONIC®, an extract of the fruit of Schisandra chinensis sold as HYALURONIC®, dehydrated oily spheres of hyaluronic acid sold under the name HYALURONIC® Filling Spheres.

[0247] Particularly advantageously, the cosmetic or dermatological composition according to the invention also comprises an extract of the fermentation culture medium of a probiotic bacterial strain.

[0248] Another subject of the present invention is the use of at least one linear fat-soluble and lipid-dispersible molecule chosen from: dicaprylyl carbonate; coco-caprylate, optionally in combination with coco-caprate, preferably a mixture of coco-caprylate and coco-caprate; undecane and / or tridecane; linoleic acid and / or oleic acid, and / or linear esters thereof (e.g. isostearyl linoleate) and / or oleyl alcohol; behenyl alcohol and / or acid and ester derivatives thereof, in particular behenic acid, otherwise expressed as behenic acid, or behenic acid esters or behenic acid esters; or any of their mixtures, for maintaining the viability of a live probiotic bacterial strain in a cosmetic or dermatological composition according to the invention, wherein said molecule or its mixture is present in a content of at least 40% by weight relative to the total weight of the composition.

[0249] This use is particularly attractive and advantageous in the presence of cosmetic or dermatological excipients, especially when the composition contains one or more branched fatty substances, especially those defined above, especially when these have a content greater than 10% by weight, preferably 20% by weight relative to the total weight of the composition and preferably between 20% and 40% by weight relative to the total weight of the composition.

[0250] The present invention also relates to the topical non-therapeutic cosmetic use of a cosmetic composition according to the invention for the cosmetic treatment of normal healthy skin and / or healthy body growths and / or healthy mucous membranes, sensitive healthy skin and / or healthy body growths and / or healthy mucous membranes, sensitized healthy skin and / or healthy body growths and / or healthy mucous membranes, fragile healthy skin and / or healthy body growths and / or healthy mucous membranes, weakened healthy skin and / or healthy body growths and / or healthy mucous membranes, healthy dry skin and / or body growths and / or mucous membranes and / or healthy skin and / or healthy mucous membranes with atopic tendency.

[0251] The present invention additionally relates to a cosmetic care method, characterized in that the method comprises topically applying a cosmetic composition according to the invention to at least one area of ​​healthy skin and / or healthy mucous membranes for the cosmetic treatment of normal healthy skin and / or healthy body surface growths and / or healthy mucous membranes, sensitive healthy skin and / or healthy body surface growths and / or healthy mucous membranes, sensitized healthy skin and / or healthy body surface growths and / or healthy mucous membranes, fragile and / or weakened healthy skin and / or healthy body surface growths and / or healthy mucous membranes, dry healthy skin and / or healthy body surface growths and / or healthy mucous membranes and healthy skin and / or healthy mucous membranes with atopic tendency.

[0252] In an advantageous embodiment of the invention, the cosmetic care method comprises topically applying a cosmetic composition according to the invention to all or part of the body and / or face, advantageously selected from the group consisting of the legs; feet; armpits; hands; thighs; buttocks; half of the buttocks; waist; crotch; groin; stomach; décolletage; neck; arms; trunk; back; face, including the forehead, cheeks, nose, temples, T-zone (forehead, nose and chin), labial mucosa, external auditory canal and / or chin; hair; and / or scalp, more preferably selected from the group consisting of the legs, feet, armpits, hands, thighs, stomach, décolletage, neck, arms, trunk, back, face, hair, nails and / or labial mucosa and / or scalp, advantageously the décolletage, face, hair, nails and / or labial mucosa, more advantageously the face; armpits, décolletage, hair, nails, labial mucosa, scalp and / or face, very advantageously the face.

[0253] In one embodiment, the amount of live probiotic bacterial strain included in the cosmetic composition does not provide a therapeutic effect.

[0254] Advantageously, another subject of the invention is a cosmetic (non-therapeutic) treatment method for preventing and / or reducing the unaesthetic and / or uncomfortable manifestations of sensitivity and / or sensitization and / or fragility and / or weakness and / or dryness and / or healthy skin and / or healthy body growths and / or healthy mucous membranes with atopic tendency in an individual in need thereof / an individual desiring it, the method comprising the following stages:

[0255] a) identifying areas of healthy skin and / or mucous membranes and / or body surface growths on an individual whose unaesthetic and / or uncomfortable manifestations are desired to be prevented and / or reduced and / or whose sensitivity and / or fragility and / or dryness and / or atopic tendencies are desired to be prevented and / or reduced, and

[0256] b) topically applying to the area of ​​healthy skin and / or healthy body growths and / or healthy mucous membranes a cosmetic composition according to the invention in an amount effective to prevent and / or reduce unaesthetic and / or uncomfortable manifestations on the area of ​​skin, body growths and / or mucous membranes and / or in an amount effective to prevent and / or reduce the sensitivity thereof and / or its fragility and / or its dryness and / or its atopic tendency.

[0257] The invention additionally relates to a dermatological composition as defined above, optionally with a cosmetically and / or dermatologically acceptable vehicle.

[0258] Cosmetically and / or dermatologically acceptable excipients may be selected from surfactants and / or emulsifiers, buffers, chelating agents, denaturants, sunscreens, pH regulators, reducing agents, stabilizers, thickeners, gelling agents, film-forming polymers, fillers, oil absorbents, glossing agents, pigments, dyes, fragrances and mixtures thereof. CTFA (Cosmetic Ingredient Handbook, 2016 edition) describes various cosmetic excipients suitable for use in the present invention. Those skilled in the art know how to adjust the formulation of the composition according to the present invention by using their general knowledge.

[0259] The present invention additionally relates to a dermatological composition according to the invention as defined above for use as an anti-inflammatory or antibacterial agent and / or for use in the treatment and / or prevention of infections of the skin and / or mucous membranes and / or growths on the body surface caused by pathogenic microorganisms, such as pathogenic yeasts or bacteria, such as Staphylococcus aureus, such as fungal diseases, eczema, seborrheic or atopic dermatitis, acne, and of inflammations of the skin or mucous membranes, fungal diseases and / or erythema, in particular diaper rash in babies, caused by pathogenic microorganisms, such as pathogenic yeasts or bacteria, such as Staphylococcus aureus, and / or in the prevention and / or medical treatment, in particular dermatological treatment, of conditions associated with reactive and / or atopic skin and / or mucous membranes.

[0260] Another subject of the present invention is a method for the treatment and / or prevention of infections of the skin and / or mucous membranes and / or body surface growths (e.g. fungal diseases, eczema, seborrheic or atopic dermatitis, acne) induced by pathogenic microorganisms (e.g. pathogenic yeasts or bacteria, such as Staphylococcus aureus), as well as inflammations of the skin or mucous membranes, fungal diseases and / or erythema, in particular diaper rash in infants, caused by pathogenic microorganisms (e.g. pathogenic yeasts or bacteria, such as Staphylococcus aureus), and / or a method for the prevention and / or medical treatment, in particular dermatological treatment, of conditions associated with reactive and / or atopic skin in a patient in need thereof, which comprises administering to the patient a pharmaceutically or dermatologically effective amount of a dermatological composition according to the invention.

[0261] Another subject of the present invention is the use of the dermatological composition according to the invention for the preparation of anti-inflammatory and / or antibacterial compositions and / or for the treatment and / or prevention of infections of the skin and / or mucous membranes and / or growths on the body surface caused by pathogenic microorganisms (e.g. pathogenic yeasts or bacteria, such as Staphylococcus aureus), such as fungal diseases, eczema, seborrheic or atopic dermatitis, acne, as well as inflammations of the skin or mucous membranes, fungal diseases and / or erythema, in particular diaper rash in babies, caused by pathogenic microorganisms (e.g. pathogenic yeasts or bacteria, such as Staphylococcus aureus) and / or medicaments for the prevention and / or medical treatment, in particular dermatological treatment of conditions associated with reactive and / or atopic skin and / or mucous membranes.

[0262] In an advantageous embodiment, the live probiotic bacterial strain is present in an amount ranging from 10 9 Colony forming units (CFU) to 10 15 CFU / g, preferably in the range of 10 9 Up to 10 13 A concentration of CFU / g is contained in the dermatological composition.

[0263] The present invention will now be described with the aid of the following examples. After reading the explanatory descriptions with reference to the examples, other objects, features and advantages of the present invention will become clearly apparent to those skilled in the art. These are presented in an indicative manner and do not limit the present invention in any way.

[0264] These examples form an integral part of the invention, and any features which appear novel in their function and general nature over any prior art from the description as a whole including these examples form an integral part of the invention.

[0265] Therefore, each instance has a common scope.

[0266] Further, in the examples and unless indicated otherwise, temperature is in degrees Celsius and pressure is atmospheric pressure.

[0267] Examples

[0268] Example 1: Preparation of a composition according to the invention

[0269] The isolated Lactobacillus crispatus bacteria (CNCM I-5579) were inoculated in a MRS type medium (Man, Rogosa, Sharpe agar) and incubated anaerobically at 37° C. The pH was maintained at a value of pH=6 and the medium was incubated for 24 h. At the end of the incubation, the entire culture medium including the bacteria was centrifuged, the cell concentrate was recovered and freeze-dried in the presence of maltodextrin, the final amount of maltodextrin being 50% by weight (w / w) relative to the total weight of the mixture.

[0270] The obtained powder, consisting of a mixture having 50% by weight of a Lactobacillus crispatus strain and 50% by weight of maltodextrin, is dispersed in 0.425% (w / w) of coco-caprylate (sold by BASF) in an amount sufficient to achieve a composition of 100% (w / w). C5).

[0271] Example 2: Monitoring of the viability of live probiotic bacteria in a composition according to the invention

[0272] plan:

[0273] According to Example 1 a composition according to the invention is obtained.

[0274] The tested composition was stored at 4°C (T4°C) and ambient temperature (Tambient, in other words between 18°C ​​and 25°C, in particular about 21°C). At the beginning of the study (T0) and at regular time intervals (T1 month, T2 months, T3 months, T6 months, T12 months and T16 months), the composition was recovered and spread on MRS (Man Sharpe Rugosa) agar. The agar was incubated at 37°C in an anaerobic jar for 3 days, and then the colonies were counted. The results are shown in Table 1 ([Table 1]) as CFU (colony forming units) / gram of composition.

[0275] result:

[0276] [Table 1]

[0277]

[0278] The tested compositions according to the invention exhibited a good maintenance of the viability of the living bacterial strains by virtue of the presence of sufficient amounts of linear, lipid-soluble and lipid-dispersible molecules.

[0279] Example 3: Comparative study of adding two linear molecules according to the present invention

[0280] plan:

[0281] Composition 1 is produced from the same initial mixture in powder form comprising 50% by weight of the Lactobacillus crispatus strain and 50% by weight of maltodextrin, dispersed at 1% (w / w) in a branched ester (in this case capric / caprylic triglyceride) in an amount sufficient to bring the composition to 100% (w / w).

[0282] The following composition 2 was produced from the same initial mixture in powder form comprising 50% by weight of the Lactobacillus crispatus strain and 50% by weight of maltodextrin:

[0283]

[0284] Phase B:

[0285] - Lactobacillus crispatus / maltodextrin mixture in a 1:1 ratio 0.42

[0286] The ingredients of phase A are mixed together at ambient temperature and then phase B is added under gentle stirring. Composition 2 contains 40% of the linear liposoluble and lipoppersible molecule according to the invention.

[0287] The viability of the probiotic bacterial strains was monitored in the same manner as in Example 2 (see [Table 2]).

[0288] result:

[0289] [Table 2]

[0290]

[0291] After one day of storage at 4° C., live bacteria were no longer measured in composition 1 comprising capric / caprylic triglycerides. The addition of a linear, liposoluble and lipopreservable molecule according to the invention in an amount of 40% by weight relative to the total weight of the composition made it possible to identify the viability of live probiotic bacterial strains.

[0292] Example 4: Comparative study of adding three linear molecules according to the present invention

[0293] Composition 3 is produced from the same initial mixture in powder form comprising 50% by weight of a Lactobacillus crispatus strain and 50% by weight of maltodextrin, dispersed at 1% (w / w) in a fatty substance composed of branched fatty chains of the alcohol type, in this case octyldodecanol, in an amount sufficient to bring the composition to 100% (w / w).

[0294] The following composition 4 was produced from the same initial mixture in powder form comprising 50% by weight of the Lactobacillus crispatus strain and 50% by weight of maltodextrin:

[0295]

[0296]

[0297] Phase B:

[0298] - Lactobacillus crispatus / maltodextrin mixture in a 1:1 ratio 0.05

[0299] The ingredients of phase A are mixed together at ambient temperature and then phase B is added under gentle stirring. Composition 4 contains 42% (w / w) of the linear lipophilic and lipopreservable molecules according to the invention (dicaprylyl carbonate, coco caprylate / caprate, and an undecane and tridecane mixture).

[0300] The viability of the probiotic bacterial strains was monitored in the same manner as in Example 2 (see [Table 3]).

[0301] result:

[0302] [Table 3]

[0303]

[0304] After two months storage at 4° C., live bacteria were no longer measured in composition 3 comprising octyldodecanol. The addition of a linear, liposoluble and lipoppersible molecule according to the invention in an amount of 42% by weight relative to the total weight of the composition made it possible to maintain the viability of the live probiotic bacterial strains.

[0305] Example 5: Comparative study of adding four linear molecules according to the present invention

[0306] The following composition 5 was produced from the same initial mixture in powder form comprising 50% by weight of the Lactobacillus crispatus strain and 50% by weight of maltodextrin:

[0307]

[0308] Phase B:

[0309] -Undecane and tridecane mixture ( Ultimate)10.00

[0310] - Lactobacillus crispatus / maltodextrin mixture in a 1:1 ratio 0.05

[0311] The ingredients of phase A were mixed together while heating at 85° C. with stirring. When phase A was homogeneous, phase B was added at 65° C. with gentle stirring, and the combined mixture was then allowed to cool to ambient temperature. Composition 5 contained 44% (w / w) of the linear, lipophilic and lipopreservable molecules according to the invention (dicaprylyl carbonate, coco-caprylate / caprate, undecane and tridecane mixture, and behenyl alcohol).

[0312] The viability of the probiotic bacterial strains was monitored in the same manner as in Example 2 (see [Table 4]).

[0313] result:

[0314] [Table 4]

[0315]

[0316]

[0317] After two months storage at 4° C., live bacteria were no longer measured in composition 3 comprising octyldodecanol. The addition of a linear, liposoluble and lipoppersible molecule according to the invention in an amount of 44% by weight relative to the total weight of the composition made it possible to maintain the viability of the live probiotic bacterial strains.

[0318] Example 6: Comparative study of linear molecules according to the invention with a content of at least 40% a) Formulation in the branched molecule squalane.

[0319] The composition is produced from the same initial mixture in powder form comprising 50% by weight of the Lactobacillus crispatus strain and 50% by weight of maltodextrin, to which 1% by weight of squalane is added relative to the total weight of the composition (squalane + Lactobacillus crispatus / maltodextrin mixture in a 1:1 ratio).

[0320] Squalane is a branched chain molecule of formula C30H62.

[0321] The viability of the probiotic bacterial strains was monitored at 4°C in the same manner as in Example 2 (see [Table 5]).

[0322] result:

[0323] [Table 5]

[0324]

[0325] After two months of storage, the viability of the live bacterial strains decreased by more than 2 log units, and at three months, no live bacteria were measured in the composition anymore. These results allow to predict that the viability of the live bacterial strains will be lost at least as fast, indeed even faster, at ambient temperature.

[0326] b) Formulations in the presence of at least 30% of linear molecules according to the invention, the following composition 6 being produced from the same initial mixture in powder form comprising 50% by weight of a Lactobacillus crispatus strain and 50% by weight of maltodextrin:

[0327]

[0328]

[0329] Phase B:

[0330] - Lactobacillus crispatus / maltodextrin mixture in a 1:1 ratio 0.05

[0331] The ingredients of phase A are mixed together while heating at 75°C with stirring. When phase A is homogeneous, phase B is added at 65°C with gentle stirring and the combined mixture is then allowed to cool to ambient temperature. Composition 6 contains at least 40% (w / w) of a linear fat-soluble and lipid-dispersible molecule according to the invention (20% of coco-caprylate / caprate) and other linear fat-soluble and lipid-dispersible molecules (rapeseed oil containing 80% oleic acid, passionflower seed oil containing at least 70% oleic acid, 7% linoleic acid, 1.4% behenic acid, 11% palmitic acid and 5% stearic acid, myristyl myristate and beeswax containing myrisin palmitate and cerotic acid (otherwise expressed as hexadecanoic acid)).

[0332] The viability of the probiotic bacterial strains was monitored in the same manner as in Example 2 (see [Table 6]).

[0333] [Table 6]

[0334]

[0335] After three months of storage at 4° C., in the composition 6) comprising squalane, no live bacteria were measured any more. The addition of a linear lipophilic and lipophilic molecule according to the invention in an amount of 40% by weight relative to the total weight of the composition and 10% by weight of other linear lipophilic and lipophilic molecules relative to the total weight of the composition made it possible to maintain the viability of the live probiotic bacterial strains. On the other hand, the presence of more than 40% of branched lipophilic and lipophilic molecules (shea butter+squalane) resulted in a reduction of 2 log units starting from 3 months, which reflects a loss of viability at ambient temperature.

[0336] PCT

[0337] Original (for submission)

[0338] (This form is not part of, and does not count as, the international application form)

[0339]

[0340] For receiving office use only

[0341] PCT

[0342] Original (for submission)

[0343] (This form is not part of, and does not count as, the international application form)

[0344]

[0345] For International Bureau use only

[0346]

Claims

1. A cosmetic and / or dermatological composition comprising: - at least one live probiotic bacterial strain, at least one linear lipid-dispersible and fat-soluble molecule chosen from: dicaprylyl carbonate; coco-caprylate, optionally in combination with coco-caprate, preferably a mixture of coco-caprylate and coco-caprate; undecane and / or tridecane; linoleic acid and / or oleic acid, and / or linear esters thereof and / or oleyl alcohol; behenyl alcohol and / or acid and ester derivatives thereof, in particular behenic acid, or behenic acid ester or behenic acid ester; and / or mixtures thereof, - and optionally one or more other linear lipid-dispersible and lipid-soluble molecules, The total content of the straight-chain lipid-dispersible and lipid-soluble molecules is at least 40% by weight relative to the total weight of the composition.

2. The cosmetic and / or dermatological composition according to the preceding claim, wherein The other straight chain lipid dispersible and fat soluble molecules are selected from: -Chemical formula C n H 2n+2 alkane molecules, wherein n represents a value ranging from 6 to 40, -Chemical formula CH3-C x H 2x -COO-C y H 2y -CH3 ester molecule, wherein each of the x and y subscripts independently represents a value ranging from 5 to 19, -Chemical formula CH3-C x H 2x -C(O)OH acid molecules, wherein x represents a value ranging from 5 to 24, preferably from 5 to 21, such as cerotic acid, -Chemical formula CH3-C x H 2x -OH alcohol molecule, wherein x represents a value ranging from 5 to 21, and any mixtures thereof.

3. The cosmetic and / or dermatological composition according to any one of the preceding claims, wherein The linear lipid-dispersible and lipid-soluble molecule chosen from the following is present in a content of at least 8% by weight, preferably at least 10% by weight, more preferably at least 15% by weight relative to the total weight of the composition: dicaprylyl carbonate; coco-caprylate, optionally in combination with coco-caprate, preferably a mixture of coco-caprylate and coco-caprate; undecane and / or tridecane; linoleic acid and / or oleic acid, and / or linear esters thereof and / or oleyl alcohol; behenyl alcohol and / or acid and ester derivatives thereof, in particular behenic acid, or behenic acid ester or behenic acid ester; and / or mixtures thereof.

4. The cosmetic and / or dermatological composition according to one of the preceding claims, wherein The straight chain lipid dispersible and lipid soluble molecule is dicaprylyl carbonate.

5. The cosmetic and / or dermatological composition according to one of the preceding claims, wherein The linear lipid dispersible and fat soluble molecule selected is coco-caprylate, optionally in combination with coco-caprate, preferably a mixture of coco-caprylate and coco-caprate.

6. The cosmetic and / or dermatological composition according to one of the preceding claims, wherein The linear lipid dispersible and lipid soluble molecule selected is dicaprylyl carbonate.

7. The cosmetic and / or dermatological composition according to one of the preceding claims, wherein The linear lipid dispersible and lipid soluble molecules selected are undecane and / or tridecane.

8. The cosmetic and / or dermatological composition according to one of the preceding claims, wherein The linear lipid dispersible and lipid soluble molecules selected are linoleic acid and / or oleic acid, and / or isostearyl linoleate and / or oleyl alcohol, preferably linoleic acid.

9. The cosmetic and / or dermatological composition according to one of the preceding claims, wherein The linear lipid dispersible and lipid soluble molecule selected is behenyl alcohol and / or its acid and ester derivatives, in particular behenic acid, or behenic acid ester or behenic acid ester, preferably behenyl alcohol.

10. The cosmetic and / or dermatological composition according to one of the preceding claims, wherein The linear lipid-dispersible and lipid-soluble molecule chosen from the following is present in a content of at least 40% by weight, preferably at least 50% by weight, more preferably at least 60% by weight relative to the total weight of the composition: dicaprylyl carbonate; coco-caprylate, optionally in combination with coco-caprate, preferably a mixture of coco-caprylate and coco-caprate; undecane and / or tridecane; linoleic acid and / or oleic acid, and / or linear esters thereof and / or oleyl alcohol; behenyl alcohol and / or acid and ester derivatives thereof, in particular behenic acid, or behenic acid ester or behenic acid ester; and / or mixtures thereof.

11. A composition as claimed in one of the preceding claims, wherein The composition comprises at least two, preferably three or four linear lipid-dispersible and lipid-soluble molecules selected from the group consisting of: dicaprylyl carbonate; coco-caprylate, optionally in combination with coco-caprate, preferably a mixture of coco-caprylate and coco-caprate; undecane and / or tridecane; linoleic acid and / or oleic acid, and / or linear esters thereof and / or oleyl alcohol; behenyl alcohol and / or acid and ester derivatives thereof, in particular behenic acid, or behenic acid ester or behenic acid ester.

12. A composition as claimed in one of the preceding claims, wherein The composition additionally comprises a branched-chain fat-soluble and lipid-dispersible molecule selected from the group consisting of octyldodecanol, propylheptyl caprylate, a mixture of caprylic and capric triglycerides, hydrogenated castor oil, shea butter, coconut oil and / or coco-glycerides.

13. A composition as claimed in one of the preceding claims, wherein The live probiotic bacterial strain is selected from the group consisting of Lactobacillus crispatus, Corynebacterium crowder, Sphingomonas glacialis, Streptococcus salivarius, and mixtures thereof.

14. A composition as claimed in one of the preceding claims, wherein The live bacterial strain is formulated from a powder obtained by freeze drying on a maltodextrin carrier, preferably in a range of 10 to 80 wt % relative to the total weight of the powder, preferably in a range of 30 to 70 wt %, more preferably in a range of 40 to 60 wt % relative to the total weight of the powder.

15. A composition as claimed in one of the preceding claims, wherein The live bacterial strain is at 10 3 Up to 10 15 The content of CFU (colony forming units) / gram of composition.

16. A composition as claimed in one of the preceding claims, wherein The live bacterial strain is present in a content ranging from 0.01% to 3% by weight relative to the total weight of the composition.

17. A composition as claimed in one of the preceding claims, wherein The water activity (Aw) of the composition is less than 0.

6.

18. The composition according to one of the preceding claims, characterized in that The composition is in the form of an oily suspension or solution, an oily cream or gel, an emulsion, a water-in-oil emulsion or a multi-type or silicone type emulsion, a mask, a serum, a lotion, a solid soap, a shampoo in solid form, a foam product in solid form, a moisturizing soap bar, an ointment, a mousse, a patch, an anhydrous product - it is preferably a liquid, a paste or a solid, for example in the form of a cosmetic powder, a stick or a bar.

19. Non-therapeutic use of a cosmetic composition according to any of the preceding claims for preventing and / or reducing unaesthetic and / or uncomfortable manifestations of healthy skin, healthy body growths and / or healthy mucous membranes, in particular sensitive or sensitized skin, body growths and / or mucous membranes, fragile or weakened skin, body growths and / or mucous membranes, dry skin, body growths and / or mucous membranes, and / or skin, body growths and / or mucous membranes with atopic tendency.

20. Non-therapeutic use of a cosmetic composition as claimed in any one of the preceding claims as a moisturiser and / or soothing agent for healthy skin, healthy body growths and / or healthy mucous membranes.

21. Non-therapeutic use of a cosmetic composition according to one of the preceding claims by topical application, preferably to areas of healthy skin, mucous membranes and / or body surface growths selected from the group consisting of: legs; feet; axillae; hands; thighs; buttocks; hemi-buttocks; waist; crotch; groin; stomach; décolletage; neck; arms; trunk; back; face; scalp; hair; nails; and / or labial mucosa, advantageously axillae, décolletage, hair, nails, labial mucosa and / or face, more advantageously face.

22. A dermatological composition as claimed in any one of claims 1 to 18 for use as an anti-inflammatory or antibacterial agent and / or for use in the treatment and / or prevention of infections of the skin and / or mucous membranes and / or growths on the body surface caused by pathogenic microorganisms such as pathogenic yeasts or bacteria such as Staphylococcus aureus, such as fungal diseases, eczema, seborrheic or atopic dermatitis, acne, and inflammations of the skin or mucous membranes, fungal diseases and / or erythema caused by pathogenic microorganisms such as pathogenic yeasts or bacteria such as Staphylococcus aureus, in particular diaper rash in infants, and / or in the prevention and / or medical treatment, in particular dermatological treatment, of conditions associated with reactive and / or atopic skin and / or mucous membranes.

23. Use of at least one linear lipid-dispersible and lipid-soluble molecule chosen from dicaprylyl carbonate; coco-caprylate, optionally in combination with coco-caprate, preferably a mixture of coco-caprylate and coco-caprate; undecane and / or tridecane; linoleic acid and / or oleic acid, and / or linear esters thereof and / or oleyl alcohol; behenyl alcohol and / or acid and ester derivatives thereof, in particular behenic acid, or behenic acid ester or behenic acid ester; and / or mixtures thereof, and optionally one or more other linear lipid-dispersible and lipid-soluble molecules for maintaining the viability of a live probiotic bacterial strain, wherein the sum of the weight of the linear lipid-dispersible and lipid-soluble molecules is at least 40% by weight relative to the total weight of the cosmetic or dermatological composition.

24. The use according to the preceding claim, characterized in that The composition is as claimed in one of claims 1 to 18.

Images